News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
22 March 2024
Molecure has submitted a new application for approval to conduct a Phase II clinical trial for clinical candidate OATD-01 in the countries of the European Union and Norway
9 February 2024
Molecure invites to the R&D Day – an online scientific and educational meeting on February 6, 2024
29 January 2024
Molecure’s success in development of the mRNA discovery platform
12 December 2023
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights
31 October 2023